Oncolytics Biotech (NASDAQ:ONCY) Insider Thomas Charles Heineman Purchases 12,132 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY) insider Thomas Charles Heineman acquired 12,132 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average cost of $0.83 per share, for a total transaction of $10,069.56. Following the purchase, the insider directly owned 282,818 shares of the company’s stock, valued at approximately $234,738.94. This trade represents a 4.48% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Oncolytics Biotech Stock Performance

ONCY stock opened at $0.83 on Friday. The company has a 50 day moving average price of $0.98 and a two-hundred day moving average price of $1.07. The stock has a market capitalization of $88.60 million, a P/E ratio of -2.98 and a beta of 0.99. Oncolytics Biotech Inc. has a one year low of $0.33 and a one year high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Research analysts forecast that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ONCY. Citadel Advisors LLC purchased a new stake in Oncolytics Biotech during the third quarter worth approximately $535,000. Tocqueville Asset Management L.P. acquired a new position in shares of Oncolytics Biotech during the 4th quarter valued at $63,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth $44,000. Scientech Research LLC purchased a new stake in Oncolytics Biotech during the 3rd quarter worth $25,000. Finally, Ground Swell Capital LLC acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $30,000. 6.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ONCY has been the topic of a number of research analyst reports. HC Wainwright raised their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Zacks Research raised shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Oncolytics Biotech has an average rating of “Moderate Buy” and an average price target of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.